



# GLAND PHARMA LIMITED

March 25, 2024

BSE Limited  
Corporate Relationship Department  
Phiroze Jeejeebhoy Towers  
25<sup>th</sup> floor, Dalal Street  
Mumbai - 400 001  
Scrip Code: 543245

National Stock Exchange of India Limited  
Listing Department  
Exchange Plaza, 5th floor  
Plot no. C-1, Block G, Bandra Kurla Complex Bandra  
(East), Mumbai - 400 051  
Symbol: GLAND (ISIN: INE068V01023)

Dear Sir/Madam,

## **Sub: Change(s) in Senior Management Personnel**

In compliance of the provisions of Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015; we would like to inform you regarding the changes among the Senior Management Personnel (“SMP”) of the Company, as approved during the meeting of the Nomination and Remuneration Committee of the Board of Directors held on 25<sup>th</sup> March, 2024 as mentioned below:

1. Mr. K.V.G.K. Raju would cease to be the Chief Technical Officer and Head of Quality of the Company with effect from the close of business hours on 29<sup>th</sup> March, 2024; due to his superannuation. Accordingly, Mr. K.V.G.K. Raju shall also cease to be Senior Management Personnel of the Company with effect from 30<sup>th</sup> March, 2024.

Mr. K.V.G.K. Raju has been associated with the Company since 18<sup>th</sup> May, 1992 and has been a strong force in heralding the Company to technological and quality excellence. The Board of Directors of the Company and the entire Gland Pharma family places on record their deep sense of appreciation for the long-standing leadership and contribution of Mr. K.V.G.K. Raju to the success of the Company.

2. Mr. K Raghuram Chandra Rao, currently serving as Vice president (Quality Assurance) shall take over as the Head-Quality of the Company and consequently, would become a Senior Management Personnel of the Company, with effect from 30<sup>th</sup> March, 2024. Mr. Raghuram has been associated with the Company since 1<sup>st</sup> December, 1999 and has overall experience of almost 25 years in Pharmaceutical industry.
3. Mr. Susheel Ogra would retire from the position of Asst. Vice President and Head of Domestic Marketing of the Company with effect from the close of business hours on 25<sup>th</sup> March, 2024 due to his superannuation. Accordingly, Mr. Susheel Ogra shall also cease to be Senior Management Personnel of the Company with effect from 26<sup>th</sup> March, 2024.

The Board of Directors of the Company and the entire Gland Pharma family places on record their deep sense of appreciation for all the efforts made by Mr. Susheel Ogra and his contribution to the success of the Company.

**Regd. Office:**  
Survey No. 143-148, 150 & 151, Near Gandimaisamma 'X' Roads  
D.P. Pally, Dundigal, Dundigal-Gandimaisamma Mandal  
Medchal-Malkajgiri District, Hyderabad 500043, Telangana, India  
Tel: +91-40-30510999 Fax: +91-40-30510800

**Corporate Office:**  
Plot No. 11 & 84, TSIIIC Phase: IV  
Pashamylaram (V), Patancheru (M), Sangareddy District  
Hyderabad 502307, Telangana, India  
Tel: +91-8455-699999



4. Mr. Surinder Koul, currently serving as General Manager (Domestic Marketing) shall assume the role of Head of Domestic Marketing of the Company and consequently would be categorized as a Senior Management Personnel of the Company with effect from 26<sup>th</sup> March, 2024.
5. Mr. Prakash Vithal Baliga, Chief Operating Officer and SMP of the Company has tendered resignation to his office in the Company to pursue other interests and opportunities. The resignation was accepted and he would be relieved from his official duties from the closure of the business hours on 30<sup>th</sup> April, 2024 and consequently he shall cease to be the SMP of the Company with effect from 1<sup>st</sup> May, 2024. Please find a copy of his resignation letter as given in **Annexure-B** enclosed herewith.

The details required under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 are given in **Annexure-A** enclosed herewith.

This is for your information and records.

**Yours truly,  
For Gland Pharma Limited**

**Sampath Kumar Pallerlamudi  
Company Secretary and Compliance Officer**

**Encl:** Annexures A & B

**Annexure A**

**Details required under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with SEBI Circular No. CIR/CFD/CMD/4/2015 dated September 9, 2015 and SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023**

**1. Details of Mr. K.V.G.K. Raju**

<b>SI. No</b>	<b>Particulars</b>	<b>Remarks</b>
1	Reason for change	Mr. K.V.G.K. Raju would cease to be the Chief Technical Officer & Head of Quality of the Company upon attaining his superannuation.
2	Date of Change	29.03.2024
3	Brief profile	Not Applicable
4	Disclosure of relationships between director	NA

**2. Details of Mr. K. Raghuram Chandra Rao**

<b>SI. No</b>	<b>Particulars</b>	<b>Remarks</b>
1	Reason for change	Mr. K Raghuram Chandra Rao shall takeover as Head of Quality of the Company with effect from 30 <sup>th</sup> March, 2024.
2	Date of Change	30.03.2024
3	Brief profile	<p>Mr. K Raghuram Chandra Rao joined Gland Pharma Limited on 1<sup>st</sup> December, 1999 as an Executive in Quality Assurance and rose to the level of Vice-President. He has more than 25 years of experience in Quality Systems.</p> <p>Mr. Raghuram has been involved in developing and executing quality systems and designing the quality metrics to regulate the quality of medicines specifically in the area of parenteral formulations. He has also been involved in training and development of various aspects of quality systems.</p> <p>He is actively involved in Production Data Acquisition (PDA) in the knowledge sharing process.</p> <p>Starting his career in academics and worked for two years before moving into the industry, Mr. Raghuram worked for brief stints with AstraZeneca and Dr. Reddy's Laboratories, prior to joining Gland Pharma.</p>



		Mr. Raghuram has done M. Pharmacy in Pharmaceutical Chemistry.
4	Disclosure of relationships between director	NA

### 3. Details of Mr. Susheel Ogra

SI. No	Particulars	Remarks
1	Reason for change	Mr. Susheel Ogra would cease to be the Asst. Vice President and Head of Domestic Marketing of the Company upon attaining his superannuation.
2	Date of Change	25.03.2024
3	Brief profile	Not Applicable
4	Disclosure of relationships between director	NA

### 4. Details of Mr. Surinder Koul

SI. No	Particulars	Remarks
1	Reason for change	Mr. Surinder Koul shall takeover as Head of the Domestic Marketing of the Company with effect from 26 <sup>th</sup> March, 2024.
2	Date of Change	26.03.2024
3	Brief profile	<p>Mr. Surinder Koul joined Gland Pharma Limited in March, 2018 as National Sales Manager and rose to the level of General Manager. He has more than 26 years of experience in Marketing of Pharmaceutical products.</p> <p>Mr. Surinder Koul started his career as a Medical Representative with ICPA Health Products and later worked with various organizations viz., Sarabhai Chemicals, Centaur Pharmaceuticals, Anglo French &amp; Drugs, and Ozone Pharmaceuticals in different roles.</p> <p>Mr. Surinder Koul is a graduate from Kashmir University</p>
4	Disclosure of relationships between director	NA

**5. Details of Mr. Prakash Vithal Baliga**

<b>Sl. No</b>	<b>Particulars</b>	<b>Remarks</b>
1	Reason for change	Mr. Prakash Vithal Baliga would cease to be the Chief Operating Officer of the Company by virtue of his resignation.
2	Date of Change	30.04.2024
3	Brief profile	Not Applicable
4	Disclosure of relationships between director	<b>NA</b>

Mr. Srinivas Sadu  
Managing Director & CEO  
Gland Pharma Limited,  
D P Pally, Dundigal Post,  
Hyderabad 500 043

29 February 2024

Dear Mr. Srinivas Sadu,

Subject: Resignation from the position of Chief Operating Officer

I wish to inform you of my desire to resign from my position as Chief Operating Officer to pursue other interests and opportunities.

It has been my privilege to be part of Gland Pharma leadership team from Sept. 2016 and contribute to milestones the company has achieved during these years and the incredible and continued growth of Gland Pharma under your leadership.

I am confident that Gland Pharma will continue as the flag bearer of regulatory compliance and market leadership and well positioned to achieve newer milestones in the years to come.

My best wishes to you and the Gland team on the journey forward.

Sincerely



Prakash Vithal Baliga

Place- Hyderabad



Accepted  
Anil  
25<sup>th</sup> March 2024